Invitrogen to Acquire Molecular Probes for $325M — Six Times Revenue

Invitrogen has bought privately held Molecular Probes for $325 million in cash — a whopping six times what the company earned in sales last year.

With the sale, expected to close during the current quarter, Invitrogen hopes to position itself in the drug-discovery and -development sector, CEO Greg Lucier said in a statement.

Molecular Probes, of Eugene, Ore., makes and sells fluorescence-based technologies. The company was founded in 1975, and had $56 million in revenues in 2002.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.